Meet with... Clarus Ventures
CIC Cambridge , Havana Room , Cambridge , MA
November 19, 2015 from 11:30 AM to 13:30 PM (EST)
$10 - $35
Clarus Ventures is a life sciences-focused investment firm with $1.7 billion under management, with offices in Boston and San Francisco. Founded in late-2005 by an experienced team with deep development expertise, Clarus has made more than 50 investments in the life sciences space.
Clarus recently announced Clarus Lifesciences III, a $500 million fund that will be split evenly between traditional venture investments and R&D risk-sharing partnerships with midcap and large pharmaceutical companies. For its venture portfolio, Clarus is seeking passionate entrepreneurs who are advancing innovative programs that target significant unmet medical needs, with an emphasis on therapeutics. Clarus invests in therapeutics at all stages of development and is agnostic as to therapeutic indication. Clarus' medtech focus is on commercial stage opportunities with disruptive potential.
Scott Requadt, Managing Director, will be presenting on November 19th. He will offer insights and lessons learned from case studies of two investments that he has been involved with -- one in therapeutics and one in medtech. Ari Brettman, MD, Associate at Clarus Ventures, as well as Scott, will also be on hand to meet with a handful of pre-approved companies one-on-one after the presentation.
To be considered for a one-on-one meeting, please complete the information required here.
10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A
12:00pm | Networking Lunch
12:30-4:00pm | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ends on October 22nd.
Clarus Ventures Participating Representatives:
Scott Requadt | Managing Director, Clarus Ventures read bio»
Ari Brettman | Associate, Clarus Ventures read bio»
About Clarus Ventures:
Clarus Ventures is a global investment firm dedicated to life sciences. Founded in 2005 by a team of accomplished investment and operating professionals, we approach healthcare investing with a passion for novel ideas and the discipline to generate attractive and predictable returns. Clarus manages $1.7 billion of assets across three funds. Through multiple platforms, we have invested in over 50 private and public companies in the biotechnology, medical device, and diagnostic spaces. Our team's expertise has enabled us to establish a long history of creating value through partnerships with Entrepreneurs, The Biopharmaceutical and Medical Technology industries to develop cutting-edge therapeutics, devices and diagnostics. Our diverse network has allowed us to source and capitalize on unique investment opportunities. In every investment, we employ a hands-on philosophy and adhere to our investment principals which are founded on our core competencies of development and clinical expertise, regulatory knowledge, and the ability to adapt to an ever-changing investment landscape. We strive to generate outstanding returns for our investors and thrive on discovering and developing innovative products that improve people's lives.
Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain open until November 18th (or sold out).
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ends on October 22nd. Your application will be reviewed and you will be notified of acceptance on November 5th. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.
Clarus Ventures Participating Representatives' Biographies:
Scott Requadt, JD, MBA | Managing Director, Clarus Ventures
Scott Requadt, JD, MBA, is currently a Managing Director for Clarus Ventures. Scott has 15+ years of operating and investment experience in the pharmaceutical industry. Prior to joining Clarus in 2005, Scott was Director, Business Development of TransForm Pharmaceuticals, Inc until it was acquired by Johnson & Johnson. At TransForm, Scott had broad responsibility for business development, corporate development and legal activities, including managing the company's intellectual property group. Prior to TransForm, Scott practiced for several years as an M&A attorney at the NYC-based law firm of Davis Polk & Wardwell, where he represented numerous private equity, pharma and technology clients. Before that, Scott was a law clerk for a senior judge at the Supreme Court of Canada. Scott holds a B.Com (Economics & Finance)from McGill University (First Class Honors), a J.D. from University of Toronto and most recently an MBA from Harvard Business School, where he was a Baker Scholar. Mr. Requadt has been involved in multiple Clarus investments spanning both therapeutics and medtech. More recently, he led Clarus' investments in a royalty interest in ibrutinib and in the IPO of Intercept Pharmaceuticals (NASDAQ:ICPT), and has been involved in several structured R&D risk-sharing investments with large pharma partners.
Connect with Scott:
Ari Brettman, MD | Associate, Clarus Ventures
Ari Brettman, MD has been an Associate at Clarus since September 2014. He joined the firm from the Massachusetts General Hospital where he completed a residency in internal medicine and a fellowship in cardiology. Dr. Brettman was also an NIH post-doctoral fellow at the MGH Center for Systems Biology, where he investigated the regulation of cellular fat storage and used big data analytics at Partners Healthcare to improve disease management. Dr. Brettman received his M.D. from Duke University and his A.B. in History and Science from Harvard College. While a medical student, he was a Sarnoff Cardiovascular Research Foundation Fellow at Stanford University, where he studied angiogenesis.
Connect with Ari:
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, NCI, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCATS, NINDS, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.